Out of 9 analysts, 4 (44.44%) are recommending CRSP as a Strong Buy, 1 (11.11%) are recommending CRSP as a...
crispr stock
Rising research and development (R&D) expenses have led to expanding losses for CRISPR Therapeutics, and the relatively nascent state of...
Top 10 Owners of CRISPR Therapeutics AG Stockholder Stake Shares owned Capital Research & Management Co. … 4.66% 3,591,160 Loomis,...
PB vs Industry: CRSP is overvalued based on its PB Ratio (2.1x) compared to the US Biotechs industry average (1.8x)....
